Skip to main content

Advertisement

SpringerLink
Log in

The Polyclonal Antibodies Induced by VBP3 Complex Peptide Targeting Angiogenesis and Tumor Suppression

  • Published:
International Journal of Peptide Research and Therapeutics Aims and scope Submit manuscript

Abstract

Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) play a critical role in tumor-associated angiogenesis and have become the targets of anti-tumor therapy. The BALB/c mice were immunized with VEGF/bFGF complex peptide (VBP3) constructed with different epitope peptides of human VEGF and bFGF. The results of the immunogenicity showed that the VBP3 could effectively stimulate immune response in mice and elicit the mice to produce high titer specific anti-VEGF and anti-bFGF antibodies (anti-VBP3 antibodies). The polyclonal anti-VBP3 antibodies separated from the mouse immune serum could effectively inhibit the proliferation, migration and tube formation of human umbilical vein endothelial cells (HUVECs) and block the proliferation and migration of lung cancer A549 cells. Besides, the anti-VBP3 antibodies could effectively inhibit tumor growth and tumor angiogenesis in BABL/c nude mice. The results demonstrated that the VBP3 complex peptide could elicit the body to produce the high titer anti-VEGF and anti-bFGF antibodies, which showed anti-tumor and anti-angiogenic effects in vitro and in vivo. The results revealed that the VBP3 complex peptide could be used as a potential peptide vaccine in tumor therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  • Abid MR et al (2004) Vascular endothelial growth factor activates PI3K/Akt/forkhead signaling in endothelial cells. Arterioscler Thrombosis Vasc Biol 24:294–300 doi:10.1161/01.atv.0000110502.10593.06

    Article  CAS  Google Scholar 

  • Aguzzi MS et al (2011) The FGF-2-derived peptide FREG inhibits melanoma growth in vitro and in vivo. Mol Ther 19:266–273. doi:10.1038/mt.2010.211

    Article  CAS  PubMed  Google Scholar 

  • Aonuma M, Yoshitake Y, Nishikawa K, Tanaka NG (1999) Different antitumor activities of anti-bFGF neutralizing antibodies: heparin-binding domain provides an inefficient epitope for neutralization in vivo. Anticancer Res 19:4039–4044

    CAS  PubMed  Google Scholar 

  • Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401–410

    Article  CAS  PubMed  Google Scholar 

  • Cai Y et al (2016) Construction of a disulfide-stabilized diabody against fibroblast growth factor-2 and the inhibition activity in targeting breast cancer. Cancer Sci 107:1141–1150. doi:10.1111/cas.12981

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cao RH, Eriksson A, Kubo H, Alitalo K, Cao YH, Thyberg J (2004) Comparative evaluation of FGF-2-, VEGF-A-, and VEGF-C-induced angiogenesis, lymphangiogenesis, vascular fenestrations, and permeability. Circ Res 94:664–670. doi:10.1161/01.res.0000118600.91698.bb

    Article  CAS  PubMed  Google Scholar 

  • Cao Y, Cao R, Hedlund E-M (2008) R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways. J Mol Med 86:785–789 doi:10.1007/s00109-008-0337-z

    Article  CAS  PubMed  Google Scholar 

  • Carmeliet P (2004) VEGF as a key mediator of angiogenesis in cancer. Int Soc Cell 69:4–10

    Google Scholar 

  • Chung AS, Ferrara N (2011) Developmental and pathological angiogenesis. In: Schekman R, Goldstein L, Lehmann R (eds) Annual review of cell and developmental biology, 27:563–584. doi:10.1146/annurev-cellbio-092910-154002

  • Cross MJ, Claesson-Welsh L (2001) FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 22:201–207. doi:10.1016/s0165-6147(00)01676-x

    Article  CAS  PubMed  Google Scholar 

  • Dvorak P, Dvorakova D, Hampl A (2006) Fibroblast growth factor signaling in embryonic and cancer stem cells. FEBS Lett 580:2869–2874 doi:10.1016/j.febslet.2006.01.095

    Article  CAS  PubMed  Google Scholar 

  • El-Manzalawy Y, Dobbs D, Honavar V (2008) Predicting linear B-cell epitopes using string kernels. J Mol Recognit 21:243–255. doi:10.1002/jmr.893

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Farhat FS et al (2012) Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer. Crit Rev Oncol Hematol 84:149–160. doi:10.1016/j.critrevonc.2012.02.012

    Article  PubMed  Google Scholar 

  • Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2:795–803

    Article  CAS  PubMed  Google Scholar 

  • Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676. doi:10.1038/nm0603-669

    Article  CAS  PubMed  Google Scholar 

  • Ferrara N, Hillan KJ, Novotny W (2005) Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333:328–335. doi:10.1016/j.bbrc.2005.05.132

    Article  CAS  PubMed  Google Scholar 

  • Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P (2011) MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol 11:856–861. doi:10.1016/j.intimp.2011.01.030

    Article  CAS  PubMed  Google Scholar 

  • Folkman J (2006) Tumor suppression by p53 is mediated in part by the antiangiogenic activity of endostatin and tumstatin. Science’s STKE 2006:pe35-pe35. doi:10.1126/stke.3542006pe35

    Google Scholar 

  • Foy KC, Miller MJ, Moldovan N, Carson WE, III, Kaumaya PTP (2012) Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo. Oncoimmunology 1:1048–1060 doi:10.4161/onci.20708

    Article  PubMed  PubMed Central  Google Scholar 

  • Foy KC, Miller MJ, Moldovan N, Carson WE, III, Kaumaya PPT (2013) Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo. Oncoimmunology 1:pg 1048, doi:10.4161/onci.23914

    Article  Google Scholar 

  • Fujio Y, Walsh K (1999) Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem 274:16349–16354. doi:10.1074/jbc.274.23.16349

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gacche RN, Meshram RJ (2014) Angiogenic factors as potential drug target: efficacy and limitations of anti-angiogenic therapy. Biochimica Et Biophysica Acta-Rev Cancer 1846:161–179. doi:10.1016/j.bbcan.2014.05.002

    Article  CAS  Google Scholar 

  • Gavilondo JV et al (2014) Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. Results of the CENTAURO antigen dose escalation phase I clinical trial. Vaccine 32:2241–2250. doi:10.1016/j.vaccine.2013.11.102

    Article  CAS  PubMed  Google Scholar 

  • Guo X, Liu T-s, Yu Y-y, Zhou Y-h, Chen Y, Zhuang R-y, Cui Y-h (2013) Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC. Zhonghua zhong liu za zhi [Chin J Oncol] 35:604–607

    CAS  Google Scholar 

  • Kano MR et al (2005) VEGF-A and FGF-2 synergistically promote neoangiogenesis through enhancement of endogenous PDGF-B-PDGFR beta signaling. J Cell Sci 118:3759–3768. doi:10.1242/jcs.02483

    Article  CAS  PubMed  Google Scholar 

  • Kaumaya PTP, Foy KC (2012) Peptide vaccines and peptidomimetics targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy. Future Oncol 8:961–987. doi:10.2217/fon.12.95

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kilvaer TK, Valkov A, Sorbye SW, Smeland E, Bremnes RM, Busund L-T, Donnem T (2011) Fibroblast growth factor 2 orchestrates angiogenic networking in non-GIST STS patients. J Translational Med 9. doi:10.1186/1479-5876-9-104

  • Kuhn H, Konrad J, Holtz S, Salameh A, Gessner C, Hammerschmidt S, Wirtz H (2006) Enhanced expression of VEGF following bFGF inhibition in non-small cell lung cancer cell lines. Lung cancer 54:149–153 doi:10.1016/j.lungcan.2006.07.016

    Article  PubMed  Google Scholar 

  • Li D et al (2010) Monoclonal antibodies targeting basic fibroblast growth factor inhibit the growth of B16 melanoma in vivo and in vitro. Oncol Rep 24:457–463. doi:10.3892/or_00000879

    CAS  PubMed  Google Scholar 

  • Li Q et al (2012) A novel bFGF antagonist peptide inhibits breast cancer cell growth. Mol Med Report 6:210–214. doi:10.3892/mmr.2012.882

    CAS  Google Scholar 

  • Liu Y, Xia X, Zhou M, Liu X (2015) Avastin (R) in combination with gemcitabine and cisplatin significantly inhibits tumor angiogenesis and increases the survival rate of human A549 tumor-bearing mice Experimental and Therapeutic. Medicine (Baltimore) 9:2180–2184. doi:10.3892/etm.2015.2402

    CAS  Google Scholar 

  • Morera Y et al (2012) Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates. Vaccine 30:368–377. doi:10.1016/j.vaccine.2011.10.082

    Article  CAS  PubMed  Google Scholar 

  • Pan L, Weng R, Zhang J, Wang J, Tang Y, Deng N (2014) Immune response of the VEGF/bFGF complex peptide vaccine and function of immune antibodies in inhibiting migration of HUVEC cells and proliferation of cancer cells. Int J Peptide Res Ther 20:565–574. doi:10.1007/s10989-014-9414-z

    Article  CAS  Google Scholar 

  • Plum SM, Holaday JW, Ruiz A, Madsen JW, Fogler WE, Fortier AH (2000) Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development. Vaccine 19:1294–1303. doi:10.1016/s0264-410x(00)00210-3

    Article  CAS  PubMed  Google Scholar 

  • Potente M, Gerhardt H, Carmeliet P (2011) Basic and therapeutic aspects of angiogenesis. Cell 146:873–887. doi:10.1016/j.cell.2011.08.039

    Article  CAS  PubMed  Google Scholar 

  • Saha S, Raghava GPS (2004) BcePred: prediction of continuous B-cell epitopes in antigenic sequences using physico-chemical properties. In: Nicosia G, Cutello V, Bentley PJ, Timmis J (eds) Artificial immune systems, proceedings, vol 3239. Lecture notes in computer science. Springer, Heidelberg, pp 197–204

    Google Scholar 

  • Sakurai T, Kudo M (2011) Signaling pathways governing tumor angiogenesis. Int Soc Cell 81:24–29. doi:10.1159/000333256

    CAS  Google Scholar 

  • Samaniego F et al (1998) Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi’s sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development. Am J Pathol 152:1433–1443

    CAS  PubMed  PubMed Central  Google Scholar 

  • Tsunenari I, Yamate J, Sharma KD, Kawachi M, Sakuma S (2000) Expressions of vascular endothelial growth factor and basic fibroblast growth factor in tumors induced by two different cloned cell lines established from transplantable rat malignant fibrous histiocytoma. J Vet Med Sci 62:699–705. doi:10.1292/jvms.62.699

    Article  CAS  PubMed  Google Scholar 

  • Wang B, Kaumaya PTP, Cohn DE (2010a) Immunization with synthetic VEGF peptides in ovarian cancer. Gynecol Oncol 119:564–570. doi:10.1016/j.ygyno.2010.07.037

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang H, Zhu Z, Yang Q, Xiang J, Yang H, Deng N (2010b) Screening the antigen epitopes of bFGF/VEGF and expressing and identifying their complex peptide. Immunol J 26:688–693

    CAS  Google Scholar 

  • Wang P et al (2012) Survivin promotes glioma angiogenesis through vascular endothelial growth factor and basic fibroblast growth factor in vitro and in vivo. Mol Carcinog 51:586–595. doi:10.1002/mc.20829

    Article  CAS  PubMed  Google Scholar 

  • Willett CG et al. (2004a) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Willett CG et al (2004b) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:649–649. doi:10.1038/nm0604-649c

    Article  CAS  Google Scholar 

  • Zhang Q et al (2015) Soluble production and function of vascular endothelial growth factor/basic fibroblast growth factor complex peptide. Biotechnol Progr 31:194–203. doi:10.1002/btpr.1997

    Article  CAS  Google Scholar 

  • Zhao M, Gao FH, Wang JY, Liu F, Yuan HH, Zhang WY, Jiang B (2011) JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer. Lung cancer 73:366–374 doi:10.1016/j.lungcan.2011.01.002

    Article  PubMed  Google Scholar 

  • Zhou M, Yu P, Qu X, Liu Y, Zhang J (2013) Phase III Trials of Standard Chemotherapy with or without Bevacizumab for Ovarian Cancer: A Meta-Analysis. Plos ONE 8. doi:10.1371/journal.pone.0081858

Download references

Acknowledgements

This work was supported by grants from the State Natural Science Foundation of China (81372281), the Shenzhen Science and Technique Plan (JCYJ20140416085544636), the Science and Technology Planning Project of Guangdong Province (2015B020211009, 2016A010105008) and the Science and Technology Planning Project of Guangzhou City (201604020099).

Author information

Author notes

    Authors and Affiliations

    1. Guangdong Province key Laboratory of Molecular Immunology and Antibody Engineering, College of Bioscience and Technology School in Jinan University, West Huangpu Avenue 601, Tianhe District, 510632, Guangzhou, China

      Yanrui Deng, Lei Pan, Ruiqiang Weng, Ligang Zhang, Zhitao Wan & Ning Deng

    2. Shenzhen Key Laboratory of Birth Defects in Baoan Maternal and Child Health Care, Affiliated Hospital in Jinan University, Shenzhen, China

      Hui Liang, Likuan Xiong & Ning Deng

    3. Dept. of Gastrointestinal Surgery, the First Clinical School in Jinan University, Guangzhou, China

      Xuejun Lao

    4. The State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-Sen University, Guangzhou, China

      Qing Zhang

    Authors
    1. Yanrui Deng
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Hui Liang
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Lei Pan
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Ruiqiang Weng
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Ligang Zhang
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Zhitao Wan
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Xuejun Lao
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Qing Zhang
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Likuan Xiong
      View author publications

      You can also search for this author in PubMed Google Scholar

    10. Ning Deng
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding authors

    Correspondence to Likuan Xiong or Ning Deng.

    Ethics declarations

    Conflict of interest

    The authors declared that they have no conflict of interest.

    Human and Animal Participants

    All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

    Informed Consent

    Informed consent was obtained from all individual participants included in the study.

    Additional information

    Yanrui Deng and Hui Liang have contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Deng, Y., Liang, H., Pan, L. et al. The Polyclonal Antibodies Induced by VBP3 Complex Peptide Targeting Angiogenesis and Tumor Suppression. Int J Pept Res Ther 23, 469–479 (2017). https://doi.org/10.1007/s10989-017-9579-3

    Download citation

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s10989-017-9579-3

    Keywords

    Search

    Navigation